Tenaya Therapeutics, Inc. (TNYA) stock intrinsic value fair value estimate & owner earnings analysis

Tenaya Therapeutics is a South San Francisco biotechnology company developing one-time gene therapies for inherited heart disease. It has no approved product and no product sales. Its two lead programs are TN-201, for hypertrophic cardiomyopathy caused by MYBPC3 mutations (the MyPEAK-1 Phase 1b/2 trial), and TN-401, for arrhythmogenic right ventricular cardiomyopathy caused by PKP2 mutations (the RIDGE-1 Phase 1b/2 trial). In November 2025 the FDA placed MyPEAK-1 on clinical hold, asking for a protocol amendment to standardize patient monitoring and management of the immune-suppression regimen across trial sites. In March 2026 Tenaya signed a research collaboration with Alnylam Pharmaceuticals to find and validate new cardiovascular gene targets: Alnylam pays an upfront fee of up to $10 million, reimburses Tenaya's staff and out-of-pocket costs for the agreed research, and could pay up to $1.1 billion in milestones on products from Tenaya-nominated targets. What the business has earned. We measure the cash the business produces for its owners each year: operating cash flow, stripped of short-term swings in working capital, less stock-based pay (a real cost that dilutes owners) and less capital spending. On that basis Tenaya has consumed cash every year: about $94 million in 2021, $136 million in 2022, $113 million in 2023, $100 million in 2024 and $79 million in 2025. The decline reflects cost cuts the company actually made: a 22% workforce reduction in May 2024, a further reduction in March 2025, and the 2025 decision to decommission its Genetic Medicines Manufacturing Center once enough TN-201 and TN-401 had been made for the current trials. The first half of 2026 ran at roughly $75 million a year on the same basis. Two accounting choices matter. Heavy 2021-2022 spending on the manufacturing center was charged in full as a cost, because a company with no sales has no revenue growth against which to call it expansion. A $21.8 million non-cash asset write-down and a gain on ending a lease in the second quarter of 2026 were excluded, since no cash moved; the Alnylam upfront payment is treated as money already in the bank rather than as recurring earnings. Because the share count grew from about 85 million to about 224 million between 2024 and mid-2026 through stock and warrant offerings, per-share losses shrank much faster than the dollar losses did. How we value it. Nothing in the filings yet shows that TN-201, TN-401 or the heart-failure drug TN-301 will be approved or sold, and the Alnylam milestones depend on discoveries that have not happened. We therefore give the pipeline no value in any case. That is not a view that the science will fail; it means no approval, sales contract or partner funding of the lead programs exists today to value. What owners can count on is the cash: $78.1 million at June 30, 2026, with no borrowings (the Silicon Valley Bank term-loan commitments expired unused). Against that sit the cash the company will spend and about $3.9 million of remaining lease obligations. The question in each case is how much of that cash is left for today's shareholders. Base case: the company does what its annual report says it will do. It keeps spending on MyPEAK-1 and RIDGE-1 through the data readouts expected in the second half of 2026 and on work toward pivotal-trial plans, at about the first-half 2026 rate of $75 million a year. That uses up almost all of the cash within about a year, which matches the company's own statement that its cash funds operations for at least twelve months from March 2026. The business holds $78.1 million, the planned spending and lease cost about $76.7 million in today's money, and roughly $1.4 million, about one cent per share, is left for current holders. Any further progress would be paid for by new investors. Bear case: spending runs at the 2025 rate of about $79 million a year, the clinical hold or a safety issue slows the trials, and the lease and wind-down costs (the 2025 workforce reduction alone cost about $2.9 million in total) still have to be paid. The cash runs out before those obligations are met. On that path the company owes about $4.5 million more than it has, roughly 2 cents per share, and would have to issue more stock at heavily dilutive prices. It has done this before: units at $0.70 in March 2025 and stock with $1.50 warrants in December 2025. Bull case: after the second-half 2026 readouts, management uses the lever it has already pulled twice. It cuts spending sharply and hands future program costs to partners, as the Alnylam deal shows it can. Only about six more months of spending (about $37.5 million) plus lease and severance costs come out of the cash, leaving about $35.6 million, roughly 16 cents per share, preserved for shareholders. Across the three cases, the shares are worth about minus 2 cents, 1 cent and 16 cents. There are also 75 million warrants exercisable at $0.80 until March 2030, 50 million at $1.50 until December 2030, and about 13.6 million employee options. All are priced above these values, so we have not counted them. If they were exercised they would bring in cash but greatly enlarge the share count. Beyond the cash, the shares mainly represent a chance on the trial results, and we cannot yet assign that chance a number. The company received a Nasdaq notice in April 2025 for trading below $1; its March 2026 annual report still lists the shares on the Nasdaq Global Select Market. What would make this wrong: a pivotal-ready result for TN-201 or TN-401 that a larger company pays to license would create value we have not counted. Signed terms of that kind would change this valuation. On the other side, a longer clinical hold or a need to keep following trial patients for years, which the MyPEAK-1 design calls for (five years of monitoring per patient), would drain cash faster than our bear case assumes.